bizjournals (Free subscription) | 11/12/2009
Endo Pharmaceuticals said late Wednesday that it will pay $23 million to intellectual property licensing and holding company LecTec Corp. to settle a patent dispute. (ENDP)
Red Orbit (Free subscription) | 11/11/2009
CHADDS FORD, Pa., Nov. 11 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos.
The Philadelphia Business Journal (Free subscription) | 11/06/2009
Endo Pharmaceuticals made a $6 million payment to Bioniche Life Sciences Inc. as part of a licensing agreement between the two companies. (ENDP)
GuruFocus Updates (Free subscription) | 10/30/2009
By 10qk. Endo Pharmaceuticals Holdings Inc. ( ENDP ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
PR News Wire (Free subscription) | 10/29/2009
CHADDS FORD, Pa., Oct. 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the third quarter of 2009.
Market Wire (Free subscription) | 10/28/2009
NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), Cintas Corp. (NASDAQ: CTAS), A123 Systems Inc. (NASDAQ: AONE), Netflix...
The Philadelphia Business Journal (Free subscription) | 10/19/2009
Endo Pharmaceuticals said Monday it expects to respond to the Food and Drug Administration's questions about the company’s new drug application for the low testosterone treatment Fortesta by mid-2010. (ENDP) (AUX)
Red Orbit (Free subscription) | 10/19/2009
CHADDS FORD, Pa., Oct. 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it received a Complete Response letter from the U.S.
PR News Wire (Free subscription) | 10/08/2009
CHADDS FORD, Pa., Oct. 8 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its third quarter financial results on October 29, 2009 and will host a conference call and webcast at 9:00 a.m. ET that day to discuss these results.
Red Orbit (Free subscription) | 10/08/2009
CHADDS FORD, Pa., Oct. 8 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its third quarter financial results on October 29, 2009 and will host a conference call and webcast at 9:00 a.m. ET that day to discuss these results. David P.
Market Wire (Free subscription) | 10/08/2009
LONDON (MARKET WIRE) Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities. Today we began research on Nalco Holding Co. (NYSE: NLC), Novavax Inc. (NASDAQ: NVAX), Cintas Corp. (NASDAQ: CTAS), Fastenal Co. (NASDAQ: FAST), Endo Pharmaceuticals Holdings Inc. (NASDAQ:...
Radon Mitigation Pittsburgh (Free subscription) | 10/06/2009
( EMAILWIRE.COM , October 06, 2009 ) Del Mar, CA Wind energy is clean, renewable, emissions-free, cost competitive and abundant, and it has become a driving force in the world's energy markets. The European Wind Energy Association reports that over 20,000 megawatts (MW) of new wind power was installed globally in 2007 to reach a total of 94,122 MW. According to the Global Wind Energy Council the wind...
MarketIntelligenceCenter.com (Free subscription) | 10/05/2009
Endo Pharmaceuticals (ENDP) was upgraded today by analysts at Oppenheimer and the stock is now at $23.55, up $1.44 (6.52%) on volume of 965,187 shares traded. The brokerage lifted ENDP to Outperform from Perform. Over the last 52 weeks the stock has ranged from a low of $13.87 to a high of $26.14. Endo Pharmaceuticals stock has been showing support around $21.71 a...
PR News Wire (Free subscription) | 09/25/2009
CHADDS FORD, Pa., Sept. 25 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the expiration and final results of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned...
Market Wire (Free subscription) | 09/25/2009
NEW DELHI, INDIA (MARKET WIRE) W.S.S. is an online community with a dedicated team of analysts who are providing free in-depth research on North American equities. Our analysts have issued free ratings reports on the following six companies: Netflix Inc. (NASDAQ: NFLX), Cintas Corp. (NASDAQ: CTAS), Novavax Inc. (NASDAQ: NVAX), Rambus Inc. (NASDAQ: RMBS), Endo Pharmaceuticals Holdings Inc. (NASDAQ:...
Videos